Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via

Weihui Guo1, Zhenyuan Qian1, Lei Wang1

  • 1Department of General Surgery, Cancer Center, Division of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Insights

Pancreatic cancer (PDAC) progression involves GNA15, which promotes M2 macrophage polarization via the STAT3-CXCL8 pathway. Targeting this axis offers a new strategy for PDAC treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) presents complex progression challenges and limited immunotherapy options.
  • G protein alpha subunit 15 (GNA15) upregulation in PDAC correlates with poor patient prognosis.

Purpose of the Study:

  • To elucidate the role of GNA15 in PDAC progression and immune modulation.
  • To identify GNA15 as a potential therapeutic target for PDAC.

Main Methods:

  • Investigated TET3-mediated GNA15 regulation via demethylation in pancreatic cancer cells (PCs).
  • Analyzed GNA15-induced STAT3 phosphorylation and CXCL8 expression through the GP130-JAK pathway.
  • Examined CXCL8's role in macrophage M2 polarization via CXCR1/CXCR2.
  • Assessed GNA15 expression's association with Gemcitabine resistance and combination therapy efficacy.

Main Results:

  • TET3 upregulates GNA15 expression in PCs via demethylation.
  • GNA15 activates STAT3 phosphorylation, promoting CXCL8 release.
  • CXCL8 drives M2 polarization in macrophages.
  • High GNA15 expression is linked to Gemcitabine resistance.
  • Combination of Reparixin and Gemcitabine showed antitumor efficacy.

Conclusions:

  • GNA15 drives PDAC progression and M2 macrophage polarization through the STAT3-CXCL8 axis.
  • Targeting the GNA15-STAT3-CXCL8 pathway represents a novel therapeutic strategy for PDAC.